# E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

> **NCT03332589** · PHASE1 · TERMINATED · sponsor: **Spirita Oncology, LLC** · enrollment: 4 (actual)

## Conditions studied

- Malignant Melanoma
- Brain Metastases

## Interventions

- **DRUG:** E6201
- **DRUG:** E6201 plus dabrafenib

## Key facts

- **NCT ID:** NCT03332589
- **Lead sponsor:** Spirita Oncology, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-02
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-10-11
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Single center study: Principal Investigator left institution.
- **Last updated:** 2022-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332589, "E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03332589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*